Tilray Tops Q2 Forecasts With Record Revenue as Stock Gains After Hours

Management detailed a push to grow Tilray Medical U.S. through FDA trials linked to potential federal rescheduling.

Overview

Tlry reported earnings of $0.01 per share versus expectations for a $0.20 loss, with revenue of $217.51 million exceeding the $210.95 million consensus and marking a company record.
Shares rose about 7% to $9.77 in extended trading, according to Benzinga Pro data.
CEO Irwin D. Simon said the company will leverage Tilray Medical U.S. infrastructure to expand research and pursue new FDA trials and development partnerships.
Investors are watching possible U.S. rescheduling to Schedule III, which could enable standard tax deductions and improve cash flow, though timing and outcomes remain uncertain.
Recent context shows weak technicals and mixed analyst sentiment, including a Jefferies Buy rating with a $2.00 target and Neutral stances from Piper Sandler ($1.00 target) and Zelman & Associates.